Skip to main content

Table 3 Characteristics of patients at baseline and after 6 months of treatment

From: Effects of a new nutraceutical combination on cognitive function in hypertensive patients

 

Baseline

6-months

Treatment effecta

MoCA test ES

   

 Control group

1.94 ± 0.94

1.83 ± 0.79

<0.001

 Active treatment group

1.89 ± 1.08

2.89 ± 1.08

Word Match Testing ES

   

 Control group

2.00 ± 0.97

1.72 ± 0.89

0.023

 Active treatment group

2.50 ± 1.20

2.94 ± 1.21

Stroop test E ES

   

 Control group

2.22 ± 0.88

1.94 ± 1.11

0.050

 Active treatment group

1.67 ± 1.65

2.00 ± 1.41

Stroop test T ES

   

 Control group

2.67 ± 0.91

2.22 ± 1.11

0.124

 Active treatment group

2.28 ± 1.67

2.61 ± 1.42

EQ-VAS

   

 Control group

65.3 ± 12.8

63.6 ± 12.3

<0.001

 Active treatment group

68.1 ± 12.8

80.6 ± 12.0

  1. Values are means ± standard deviation
  2. MoCa = Montreal Cognitive Assessment; ES = equivalent score; EQ-VAS = EQ-5D test visual analogue scale
  3. a = active treatment versus placebo, GLM analysis
Back to article page

Immunity & Ageing

ISSN: 1742-4933

Contact us